UB401
TargetsUSP1
IndicationsSolid tumour
ClinicalCN - IND
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- No significant inhibition of the CYP metabolic pathway, making it favorable for combination therapy.
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →